HCM
PLX icon

Highlander Capital Management’s Protalix BioTherapeutics PLX Stock Holding History

Highlander Capital Management’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$769 Hold
610
– – ﹤0.01% 888
2023
Q4 		$1.09K Hold
610
– – ﹤0.01% 903
2023
Q3 		$1K Buy
+610
New +$1.09K ﹤0.01% 879

Other funds holding PLX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Highlander Capital Management's PLX Position: Q1 2024 in Review

Highlander Capital Management held its Protalix BioTherapeutics (PLX) position steady in Q1 2024 at 610 shares worth $769. The position accounts for ﹤0.01% of the portfolio, ranked #888.

Highlander Capital Management first reported a position in PLX in Q3 2023 and has held it in 3 quarters since. The position peaked at $1.09K in Q4 2023. 63 funds tracked by Wall St. Rank hold PLX as of Q1 2024.

  • Highlander Capital Management held 610 shares of Protalix BioTherapeutics worth $769 as of Q1 2024.
  • Highlander Capital Management left its Protalix BioTherapeutics share count unchanged in Q1 2024.
  • Protalix BioTherapeutics made up ﹤0.01% of Highlander Capital Management's portfolio in Q1 2024, its #888 holding.
  • Highlander Capital Management first reported a position in Protalix BioTherapeutics in Q3 2023 and has held it in 3 quarters since.
  • Highlander Capital Management's Protalix BioTherapeutics position peaked at $1.09K in Q4 2023.
  • 63 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2024.

Based on Highlander Capital Management's 13F filing for Q1 2024, filed 20 May 2024.